Rubric Capital Management LP: ARCUTIS BIOTHERAPEUTICS INC (ARQT): Quarterly 13F Position History
As of Q1 2026, Rubric Capital Management LP reported 8,271,577 shares of ARCUTIS BIOTHERAPEUTICS INC (ARQT), worth $194.9M and representing 2.4% of its 13F equity book. The position first appeared in Q3 2022 and has been disclosed across 15 13F-HR filings in Pactolio's tracked window.
- 8,271,577Shares Held (Latest Filing)
- $194.9MReported Market Value (Latest Filing)
- 2.4%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- -$45.3MQuarter-over-Quarter Value Change
- 10,966,672Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 15 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 8,271,577 | 0 | — | $194.9M | 2.4% | $23.6 |
| Q4 2025 | 8,271,577 | 2,477,880 | -23.1% | $240.2M | 2.9% | $29.0 |
| Q3 2025 | 10,749,457 | 0 | — | $202.6M | 2.7% | $18.9 |
| Q2 2025 | 10,749,457 | 217,215 | -2.0% | $150.7M | 2.4% | $14.0 |
| Q1 2025 | 10,966,672 | 0 | — | $171.5M | 3.1% | $15.6 |
| Q4 2024 | 10,966,672 | 0 | — | $152.8M | 2.8% | $13.9 |
| Q3 2024 | 10,966,672 | +1,150,000 | +11.7% | $102.0M | 1.7% | $9.3 |
| Q2 2024 | 9,816,672 | +2,306,672 | +30.7% | $91.3M | 2.4% | $9.3 |
| Q1 2024 | 7,510,000 | +865,470 | +13.0% | $74.4M | 2.2% | $9.9 |
| Q4 2023 | 6,644,530 | +1,610,000 | +32.0% | $21.5M | 0.8% | $3.2 |
| Q3 2023 | 5,034,530 | +150,000 | +3.1% | $26.7M | 1.1% | $5.3 |
| Q2 2023 | 4,884,530 | +1,384,530 | +39.6% | $46.5M | 2.0% | $9.5 |
| Q1 2023 | 3,500,000 | +757,481 | +27.6% | $38.5M | 1.5% | $11.0 |
| Q4 2022 | 2,742,519 | +2,270,472 | +481.0% | $40.6M | 1.8% | $14.8 |
| Q3 2022 | 472,047 | — | — | $9.0M | 0.5% | $19.1 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Rubric Capital Management LP first disclose a ARQT position in 13F-HR filings?
Rubric Capital Management LP first reported ARCUTIS BIOTHERAPEUTICS INC (ARQT) on its 13F-HR filing for the period ending 2022-09-30 (Q3 2022). The position has appeared on 15 reported quarters within Pactolio's tracked window.
What was Rubric Capital Management LP's most recent quarter-over-quarter share-count change in ARQT?
Rubric Capital Management LP held the same 8,271,577 shares of ARQT between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent Rubric Capital Management LP's cost basis in ARQT?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.